Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commerc...
June 22 2018 - 6:15PM
Real-World
Experience Data on Sugar.IQ App Use Presented
at the 78th Scientific Sessions of the American
Diabetes Association
DUBLIN AND CAMBRIDGE - June 22,
2018 - Medtronic plc (NYSE:MDT), the global leader in medical
technology, services and solutions, and its strategic technology
partner, IBM (NYSE:IBM) Watson Health, today announced commercial
availability of the Sugar.IQ(TM) smart diabetes assistant, a
first-of-its-kind intelligent app designed to simplify and improve
daily diabetes management.
Approximately 30.3 million Americans have been
diagnosed with diabetes, with 1.5 million new cases being diagnosed
every year.1 More than 6
million of those impacted use insulin to manage their
diabetes.2 People with
diabetes face many daily challenges - managing their condition,
understanding medical advice, knowing what to eat and when, the
impact of food and activity on sugar levels, and trying to avoid
critical glycemic events. The groundbreaking Sugar.IQ smart
diabetes assistant leverages artificial intelligence (AI) and
analytic technologies from IBM Watson Health to continually analyze
how an individual's glucose level responds to their food intake,
insulin dosages, daily routines, and other factors, such as
information provided by the app user.
For example, are certain foods worsening the
patient's glucose control? Are there particular days or times where
a person's glucose goes high or low? With Sugar.IQ, people with
diabetes can uncover patterns that affect their glucose levels
which can help them make small adjustments throughout the day to
help stay on track.
Medtronic and IBM Watson Health leveraged their
combined expertise in diabetes, AI and analytics to develop the
Sugar.IQ diabetes assistant. The Sugar.IQ assistant reveals
patterns that may be hard to see so that someone with diabetes
gains meaningful, personalized insights. These insights show how
lifestyle choices, medications, and multiple daily injections
impact diabetes management and the time spent with glucose in the
target range. The app uses AI and advanced analytics to give users
a full picture of their current levels and provides insights and
individualized guidance in understanding and managing daily
diabetes management decisions, so that people on multiple daily
insulin injections have more freedom to enjoy life.
In data presented at the 78th Annual American
Diabetes Association (ADA) Scientific Sessions on June 22, 2018,
people who used the Sugar.IQ app spent 36 minutes more per day in
healthy glucose range than they did before using the app. This
included 30 minutes less time in hyperglycemia (>180 mg/dL) and
6 minutes less time in hypoglycemia (<70 mg/dL).3
This represents more than 9 additional days in a year that a person
with diabetes is spending in a healthy glucose range.
According to Michelle Shaw, a Medtronic employee
and registered nurse (RN) who has been using the Sugar.IQ app for 4
weeks through an employee preview program, "Sugar.IQ has given me
insights that I could never have uncovered on my own - even with 30
years of diabetes experience. It's been eye opening and fun to gain
new insights into my diabetes without additional burden."
The Sugar.IQ app is available to users of the
Medtronic Guardian(TM) Connect system, the first smart standalone
CGM system4 designed to
empower people with diabetes using multiple daily injections (MDI)
with actionable tools to help them get ahead of high and low
glucose levels - not just react to them. With customizable
predictive alerts up to 60 minutes before a high or low, and the
Sugar.IQ assistant, Guardian Connect CGM provides people with more
tools to stay in range than any other CGM system.5
The Sugar.IQ app is available for iOS-based mobile
devices in the U.S.
Devices alone cannot transform diabetes care. The
combination of patient engagement, technologies, big data and
analytics, informatics and world-class patient management are all
required to drive effective results in diabetes care. By leveraging
Medtronic devices and care management offerings-including therapies
and coaching-and with IBM Watson Health's powerful analytic and AI
capabilities, Medtronic can leverage data-driven insights to help
people with diabetes and their caregivers.
|
|
|
Sugar.IQ Insight Sample
|
Sugar.IQ My Data Sample
|
Sugar.IQ Glycemic Assist
Sample
|
The Sugar.IQ assistant from Medtronic and IBM Watson Health
reveals patterns that may be hard to see so that someone with
diabetes gains meaningful, personalized insights. These insights
show how lifestyle choices, medications, and multiple daily
injections impact diabetes management and the time spent with
glucose in the target range. |
Click the thumbnails above for a larger image. |
About IBM Watson
Health
Watson Health is a business unit of IBM that is dedicated to the
development and implementation of AI and data-driven technologies
to advance health. Watson Health technologies are tackling a wide
range of the world's biggest healthcare challenges including
cancer, diabetes, drug discovery and more. Learn more
at ibm.com/watson/health.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 86,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 American
Diabetes Association, Overall Numbers, Diabetes and Prediabetes,
March 22, 2018
2 American
Diabetes Association, Fast Facts: Data and Statistics about
Diabetes, December 2015
3 Usage of
Sugar.IQ app was analyzed based on data from 256 randomly offered
real-world MiniMed 530G users from April to August 2017
4Smart CGM
predicts future high and low sensor glucose events and provides
access to additional algorithms and insights that can inform users
of clinically relevant glucose patterns
5
Decision-making around insulin dosages should always follow the
guidance of a patient's healthcare professional.
Contacts:
Pamela Reese
Medtronic
Public Relations
+1-818-576-3398
Ryan Weispfenning
Medtronic
Investor Relations
+1-763-505-4626
Kristi Bond
Watson Health Communications
+1-802-345-8313
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024